PLVAP

Across TCGA pan-cancer cohorts, PLVAP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLVAP data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLVAP mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLVAP expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where PLVAP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.855	0.510	.014	14	view →
LUAD	OS	Quartile	II,III,IV	0.822	1.000	.019	14	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
PDAC	DFS	Tertile	IV	0.959	0.409	.049	6	view →
HNSC	OS	Tertile	II,III,IV	0.837	0.650	.023	5	view →
LSCC	DFS	Tertile	II,III,IV	0.791	0.945	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLVAP–CCRCC (DFS)

Open the CCRCC breakdown →